APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hormone Antineoplastic Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Hormone Antineoplastic Drugs Industry Growth and Trends Forecast to 2032

22 December 2025101 pages

Choose your research edition.

Industry ResearchHormone Antineoplastic Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Hormone Antineoplastic Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Hormone Antineoplastic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hormone Antineoplastic Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Hormone Antineoplastic Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Hormone Antineoplastic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hormone Antineoplastic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hormone Antineoplastic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hormone Antineoplastic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hormone Antineoplastic Drugs include Zhengzhou Lingfang Chemical Co., Ltd., Kono, DC chemicals, Medbio, Acmec, Aladdin, Revere, Pfizer Inc. and Baxter International Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hormone Antineoplastic Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hormone Antineoplastic Drugs market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hormone Antineoplastic Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hormone Antineoplastic Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hormone Antineoplastic Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hormone Antineoplastic Drugs Market by Company

Zhengzhou Lingfang Chemical Co., Ltd.

Kono

DC chemicals

Medbio

Acmec

Aladdin

Revere

Pfizer Inc.

Baxter International Inc.

Hikma Pharmaceuticals Plc.

Hormone Antineoplastic Drugs Segment by Type

Progesterone

Androgens

Glucocorticoids

Antiandrogens

Antiestrogens

Estrogens

Hormone Antineoplastic Drugs Segment by Application

Leukemia Treatment

Multiple Myeloma Treatment

Lymphoma Treatment

Hormone Antineoplastic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hormone Antineoplastic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hormone Antineoplastic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hormone Antineoplastic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hormone Antineoplastic Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Hormone Antineoplastic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Progesterone Table 2. Major Company of Androgens Table 3. Major Company of Glucocorticoids Table 4. Major Company of Antiandrogens Table 5. Major Company of Antiestrogens Table 6. Major Company of Estrogens Table 7. Global Hormone Antineoplastic Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (k units) Table 9. Global Hormone Antineoplastic Drugs Sales Market Share in Volume by Type (2021-2026) Table 10. Global Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (US$ Million) Table 11. Global Hormone Antineoplastic Drugs Sales Market Share in Value by Type (2021-2026) Table 12. Global Hormone Antineoplastic Drugs Price by Type (2021-2026) & (US$/unit) Table 13. Global Hormone Antineoplastic Drugs Sales by Type (2027-2032) & (k units) Table 14. Global Hormone Antineoplastic Drugs Sales Market Share in Volume by Type (2027-2032) Table 15. Global Hormone Antineoplastic Drugs Sales by Type (2027-2032) & (US$ Million) Table 16. Global Hormone Antineoplastic Drugs Sales Market Share in Value by Type (2027-2032) Table 17. Global Hormone Antineoplastic Drugs Price by Type (2027-2032) & (US$/unit) Table 18. North America Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (k units) Table 19. North America Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (k units) Table 21. Europe Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (k units) Table 23. Asia-Pacific Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (k units) Table 25. Latin America Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (k units) Table 27. Middle East and Africa Hormone Antineoplastic Drugs Sales by Type (2021-2026) & (US$ Million) Table 28. Hormone Antineoplastic Drugs Industry Trends Table 29. Hormone Antineoplastic Drugs Industry Drivers Table 30. Hormone Antineoplastic Drugs Industry Opportunities and Challenges Table 31. Hormone Antineoplastic Drugs Industry Restraints Table 32. Global Hormone Antineoplastic Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Hormone Antineoplastic Drugs Revenue Market Share by Company (2021-2026) Table 34. Global Hormone Antineoplastic Drugs Sales by Company (2021-2026) & (k units) Table 35. Global Hormone Antineoplastic Drugs Sales Share by Company (2021-2026) Table 36. Global Hormone Antineoplastic Drugs Market Price by Company (2021-2026) & (US$/unit) Table 37. Global Hormone Antineoplastic Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Hormone Antineoplastic Drugs Major Company Production Sites and Headquarters Table 39. Global Hormone Antineoplastic Drugs Company, Product Type & Application Table 40. Global Hormone Antineoplastic Drugs Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Hormone Antineoplastic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Hormone Antineoplastic Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Hormone Antineoplastic Drugs Sales by Region (2021-2026) & (k units) Table 45. Global Hormone Antineoplastic Drugs Sales Market Share in Volume by Region (2021-2026) Table 46. Global Hormone Antineoplastic Drugs Sales by Region (2021-2026) & (US$ Million) Table 47. Global Hormone Antineoplastic Drugs Sales Market Share in Value by Region (2021-2026) Table 48. Global Hormone Antineoplastic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 49. Global Hormone Antineoplastic Drugs Sales by Region (2027-2032) & (k units) Table 50. Global Hormone Antineoplastic Drugs Sales Market Share in Volume by Region (2027-2032) Table 51. Global Hormone Antineoplastic Drugs Sales by Region (2027-2032) & (US$ Million) Table 52. Global Hormone Antineoplastic Drugs Sales Market Share in Value by Region (2027-2032) Table 53. Global Hormone Antineoplastic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 54. Global Hormone Antineoplastic Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (k units) Table 56. Global Hormone Antineoplastic Drugs Sales Market Share in Volume by Application (2021-2026) Table 57. Global Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (US$ Million) Table 58. Global Hormone Antineoplastic Drugs Sales Market Share in Value by Application (2021-2026) Table 59. Global Hormone Antineoplastic Drugs Price by Application (2021-2026) & (US$/unit) Table 60. Global Hormone Antineoplastic Drugs Sales by Application (2027-2032) & (k units) Table 61. Global Hormone Antineoplastic Drugs Sales Market Share in Volume by Application (2027-2032) Table 62. Global Hormone Antineoplastic Drugs Sales by Application (2027-2032) & (US$ Million) Table 63. Global Hormone Antineoplastic Drugs Sales Market Share in Value by Application (2027-2032) Table 64. Global Hormone Antineoplastic Drugs Price by Application (2027-2032) & (US$/unit) Table 65. North America Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (k units) Table 66. North America Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (k units) Table 68. Europe Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (k units) Table 70. Asia-Pacific Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (k units) Table 72. Latin America Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (k units) Table 74. Middle East and Africa Hormone Antineoplastic Drugs Sales by Application (2021-2026) & (US$ Million) Table 75. Zhengzhou Lingfang Chemical Co., Ltd. Company Information Table 76. Zhengzhou Lingfang Chemical Co., Ltd. Business Overview Table 77. Zhengzhou Lingfang Chemical Co., Ltd. Hormone Antineoplastic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Zhengzhou Lingfang Chemical Co., Ltd. Hormone Antineoplastic Drugs Product Portfolio Table 79. Zhengzhou Lingfang Chemical Co., Ltd. Recent Development Table 80. Kono Company Information Table 81. Kono Business Overview Table 82. Kono Hormone Antineoplastic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Kono Hormone Antineoplastic Drugs Product Portfolio Table 84. Kono Recent Development Table 85. DC chemicals Company Information Table 86. DC chemicals Business Overview Table 87. DC chemicals Hormone Antineoplastic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. DC chemicals Hormone Antineoplastic Drugs Product Portfolio Table 89. DC chemicals Recent Development Table 90. Medbio Company Information Table 91. Medbio Business Overview Table 92. Medbio Hormone Antineoplastic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Medbio Hormone Antineoplastic Drugs Product Portfolio Table 94. Medbio Recent Development Table 95. Acmec Company Information Table 96. Acmec Business Overview Table 97. Acmec Hormone Antineoplastic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Acmec Hormone Antineoplastic Drugs Product Portfolio Table 99. Acmec Recent Development Table 100. Aladdin Company Information Table 101. Aladdin Business Overview Table 102. Aladdin Hormone Antineoplastic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Aladdin Hormone Antineoplastic Drugs Product Portfolio Table 104. Aladdin Recent Development Table 105. Revere Company Information Table 106. Revere Business Overview Table 107. Revere Hormone Antineoplastic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Revere Hormone Antineoplastic Drugs Product Portfolio Table 109. Revere Recent Development Table 110. Pfizer Inc. Company Information Table 111. Pfizer Inc. Business Overview Table 112. Pfizer Inc. Hormone Antineoplastic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Pfizer Inc. Hormone Antineoplastic Drugs Product Portfolio Table 114. Pfizer Inc. Recent Development Table 115. Baxter International Inc. Company Information Table 116. Baxter International Inc. Business Overview Table 117. Baxter International Inc. Hormone Antineoplastic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Baxter International Inc. Hormone Antineoplastic Drugs Product Portfolio Table 119. Baxter International Inc. Recent Development Table 120. Hikma Pharmaceuticals Plc. Company Information Table 121. Hikma Pharmaceuticals Plc. Business Overview Table 122. Hikma Pharmaceuticals Plc. Hormone Antineoplastic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Hikma Pharmaceuticals Plc. Hormone Antineoplastic Drugs Product Portfolio Table 124. Hikma Pharmaceuticals Plc. Recent Development Table 125. North America Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 126. North America Hormone Antineoplastic Drugs Sales by Country (2021-2026) & (k units) Table 127. North America Hormone Antineoplastic Drugs Sales Market Share by Country (2021-2026) Table 128. North America Hormone Antineoplastic Drugs Sales Forecast by Country (2027-2032) & (k units) Table 129. North America Hormone Antineoplastic Drugs Sales Market Share Forecast by Country (2027-2032) Table 130. North America Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 131. North America Hormone Antineoplastic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 132. North America Hormone Antineoplastic Drugs Market Share by Country (2021-2026) Table 133. North America Hormone Antineoplastic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 134. North America Hormone Antineoplastic Drugs Market Share Forecast by Country (2027-2032) Table 135. Europe Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 136. Europe Hormone Antineoplastic Drugs Sales by Country (2021-2026) & (k units) Table 137. Europe Hormone Antineoplastic Drugs Sales Market Share by Country (2021-2026) Table 138. Europe Hormone Antineoplastic Drugs Sales Forecast by Country (2027-2032) & (k units) Table 139. Europe Hormone Antineoplastic Drugs Sales Market Share Forecast by Country (2027-2032) Table 140. Europe Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 141. Europe Hormone Antineoplastic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 142. Europe Hormone Antineoplastic Drugs Market Share by Country (2021-2026) Table 143. Europe Hormone Antineoplastic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 144. Europe Hormone Antineoplastic Drugs Market Share Forecast by Country (2027-2032) Table 145. Asia-Pacific Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 146. Asia-Pacific Hormone Antineoplastic Drugs Sales by Country (2021-2026) & (k units) Table 147. Asia-Pacific Hormone Antineoplastic Drugs Sales Market Share by Country (2021-2026) Table 148. Asia-Pacific Hormone Antineoplastic Drugs Sales Forecast by Country (2027-2032) & (k units) Table 149. Asia-Pacific Hormone Antineoplastic Drugs Sales Market Share Forecast by Country (2027-2032) Table 150. Asia-Pacific Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 151. Asia-Pacific Hormone Antineoplastic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 152. Asia-Pacific Hormone Antineoplastic Drugs Market Share by Country (2021-2026) Table 153. Asia-Pacific Hormone Antineoplastic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 154. Asia-Pacific Hormone Antineoplastic Drugs Market Share Forecast by Country (2027-2032) Table 155. Latin America Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 156. Latin America Hormone Antineoplastic Drugs Sales by Country (2021-2026) & (k units) Table 157. Latin America Hormone Antineoplastic Drugs Sales Market Share by Country (2021-2026) Table 158. Latin America Hormone Antineoplastic Drugs Sales Forecast by Country (2027-2032) & (k units) Table 159. Latin America Hormone Antineoplastic Drugs Sales Market Share Forecast by Country (2027-2032) Table 160. Latin America Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 161. Latin America Hormone Antineoplastic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 162. Latin America Hormone Antineoplastic Drugs Market Share by Country (2021-2026) Table 163. Latin America Hormone Antineoplastic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 164. Latin America Hormone Antineoplastic Drugs Market Share Forecast by Country (2027-2032) Table 165. Middle East and Africa Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 166. Middle East and Africa Hormone Antineoplastic Drugs Sales by Country (2021-2026) & (k units) Table 167. Middle East and Africa Hormone Antineoplastic Drugs Sales Market Share by Country (2021-2026) Table 168. Middle East and Africa Hormone Antineoplastic Drugs Sales Forecast by Country (2027-2032) & (k units) Table 169. Middle East and Africa Hormone Antineoplastic Drugs Sales Market Share Forecast by Country (2027-2032) Table 170. Middle East and Africa Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 171. Middle East and Africa Hormone Antineoplastic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 172. Middle East and Africa Hormone Antineoplastic Drugs Market Share by Country (2021-2026) Table 173. Middle East and Africa Hormone Antineoplastic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 174. Middle East and Africa Hormone Antineoplastic Drugs Market Share Forecast by Country (2027-2032) Table 175. Key Raw Materials Table 176. Raw Materials Key Suppliers Table 177. Hormone Antineoplastic Drugs Distributors List Table 178. Hormone Antineoplastic Drugs Customers List Table 179. Research Programs/Design for This Report Table 180. Authors List of This Report Table 181. Secondary Sources Table 182. Primary Sources List of Figures Figure 1. Hormone Antineoplastic Drugs Image Figure 2. Global Hormone Antineoplastic Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hormone Antineoplastic Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Hormone Antineoplastic Drugs Sales (2021-2032) & (k units) Figure 5. Progesterone Image Figure 6. Global Progesterone Sales YoY Growth (2021-2032) & (k units) Figure 7. Androgens Image Figure 8. Global Androgens Sales YoY Growth (2021-2032) & (k units) Figure 9. Glucocorticoids Image Figure 10. Global Glucocorticoids Sales YoY Growth (2021-2032) & (k units) Figure 11. Antiandrogens Image Figure 12. Global Antiandrogens Sales YoY Growth (2021-2032) & (k units) Figure 13. Antiestrogens Image Figure 14. Global Antiestrogens Sales YoY Growth (2021-2032) & (k units) Figure 15. Estrogens Image Figure 16. Global Estrogens Sales YoY Growth (2021-2032) & (k units) Figure 17. Global Hormone Antineoplastic Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Hormone Antineoplastic Drugs Market Share by Type 2025 VS 2032 Figure 19. North America Hormone Antineoplastic Drugs Sales Market Share in Volume by Type in 2025 Figure 20. North America Hormone Antineoplastic Drugs Sales Market Share in Value by Type in 2025 Figure 21. Europe Hormone Antineoplastic Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Europe Hormone Antineoplastic Drugs Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Hormone Antineoplastic Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Hormone Antineoplastic Drugs Sales Market Share in Value by Type in 2025 Figure 25. Latin America Hormone Antineoplastic Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Hormone Antineoplastic Drugs Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Hormone Antineoplastic Drugs Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Hormone Antineoplastic Drugs Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Hormone Antineoplastic Drugs Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Leukemia Treatment Image Figure 32. Global Leukemia Treatment Sales YoY Growth (2021-2032) & (k units) Figure 33. Multiple Myeloma Treatment Image Figure 34. Global Multiple Myeloma Treatment Sales YoY Growth (2021-2032) & (k units) Figure 35. Lymphoma Treatment Image Figure 36. Global Lymphoma Treatment Sales YoY Growth (2021-2032) & (k units) Figure 37. Global Hormone Antineoplastic Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Hormone Antineoplastic Drugs Market Share by Application 2025 VS 2032 Figure 39. North America Hormone Antineoplastic Drugs Sales Market Share in Volume by Application in 2025 Figure 40. North America Hormone Antineoplastic Drugs Sales Market Share in Value by Application in 2025 Figure 41. Europe Hormone Antineoplastic Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Europe Hormone Antineoplastic Drugs Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Hormone Antineoplastic Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Hormone Antineoplastic Drugs Sales Market Share in Value by Application in 2025 Figure 45. Latin America Hormone Antineoplastic Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Hormone Antineoplastic Drugs Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Hormone Antineoplastic Drugs Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Hormone Antineoplastic Drugs Sales Market Share in Value by Application in 2025 Figure 49. North America Hormone Antineoplastic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. North America Hormone Antineoplastic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Hormone Antineoplastic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Hormone Antineoplastic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Hormone Antineoplastic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Europe Hormone Antineoplastic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Hormone Antineoplastic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Hormone Antineoplastic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Hormone Antineoplastic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Asia-Pacific Hormone Antineoplastic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Hormone Antineoplastic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Hormone Antineoplastic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Hormone Antineoplastic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Latin America Hormone Antineoplastic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Hormone Antineoplastic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Hormone Antineoplastic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Hormone Antineoplastic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. Middle East and Africa Hormone Antineoplastic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Hormone Antineoplastic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Hormone Antineoplastic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Hormone Antineoplastic Drugs Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Hormone Antineoplastic Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Progesterone
  • Androgens
  • Glucocorticoids
  • Antiandrogens
  • Antiestrogens
  • Estrogens
Applications
  • Leukemia Treatment
  • Multiple Myeloma Treatment
  • Lymphoma Treatment
Companies covered
  • Zhengzhou Lingfang Chemical Co., Ltd.
  • Kono
  • DC chemicals
  • Medbio
  • Acmec
  • Aladdin
  • Revere
  • Pfizer Inc.
  • Baxter International Inc.
  • Hikma Pharmaceuticals Plc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hormone Antineoplastic Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Hormone Antineoplastic Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Hormone Antineoplastic Drugs Market by Type
  6. 1.3.1 Progesterone
  7. 1.3.2 Androgens
  8. 1.3.3 Glucocorticoids
  9. 1.3.4 Antiandrogens
  10. 1.3.5 Antiestrogens
  11. 1.3.6 Estrogens
  12. 1.4 Global Hormone Antineoplastic Drugs Market Size by Type
  13. 1.4.1 Global Hormone Antineoplastic Drugs Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Hormone Antineoplastic Drugs Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Hormone Antineoplastic Drugs Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Hormone Antineoplastic Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Hormone Antineoplastic Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Hormone Antineoplastic Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Hormone Antineoplastic Drugs Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Hormone Antineoplastic Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Hormone Antineoplastic Drugs Industry Trends
  2. 2.2 Hormone Antineoplastic Drugs Industry Drivers
  3. 2.3 Hormone Antineoplastic Drugs Industry Opportunities and Challenges
  4. 2.4 Hormone Antineoplastic Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Hormone Antineoplastic Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Hormone Antineoplastic Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Hormone Antineoplastic Drugs Price (2021-2026)
  4. 3.4 Global Hormone Antineoplastic Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hormone Antineoplastic Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Hormone Antineoplastic Drugs Company, Product Type & Application
  7. 3.7 Global Hormone Antineoplastic Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hormone Antineoplastic Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hormone Antineoplastic Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hormone Antineoplastic Drugs Tier 1, Tier 2, and Tier 3
4 Hormone Antineoplastic Drugs Regional Status and Outlook
  1. 4.1 Global Hormone Antineoplastic Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Hormone Antineoplastic Drugs Historic Market Size by Region
  3. 4.2.1 Global Hormone Antineoplastic Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Hormone Antineoplastic Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Hormone Antineoplastic Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Hormone Antineoplastic Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Hormone Antineoplastic Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Hormone Antineoplastic Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Hormone Antineoplastic Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Hormone Antineoplastic Drugs by Application
  1. 5.1 Hormone Antineoplastic Drugs Market by Application
  2. 5.1.1 Leukemia Treatment
  3. 5.1.2 Multiple Myeloma Treatment
  4. 5.1.3 Lymphoma Treatment
  5. 5.2 Global Hormone Antineoplastic Drugs Market Size by Application
  6. 5.2.1 Global Hormone Antineoplastic Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Hormone Antineoplastic Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Hormone Antineoplastic Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Hormone Antineoplastic Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Hormone Antineoplastic Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Hormone Antineoplastic Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Hormone Antineoplastic Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Hormone Antineoplastic Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Zhengzhou Lingfang Chemical Co., Ltd.
  2. 6.1.1 Zhengzhou Lingfang Chemical Co., Ltd. Company Information
  3. 6.1.2 Zhengzhou Lingfang Chemical Co., Ltd. Business Overview
  4. 6.1.3 Zhengzhou Lingfang Chemical Co., Ltd. Hormone Antineoplastic Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Zhengzhou Lingfang Chemical Co., Ltd. Hormone Antineoplastic Drugs Product Portfolio
  6. 6.1.5 Zhengzhou Lingfang Chemical Co., Ltd. Recent Developments
  7. 6.2 Kono
  8. 6.2.1 Kono Company Information
  9. 6.2.2 Kono Business Overview
  10. 6.2.3 Kono Hormone Antineoplastic Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Kono Hormone Antineoplastic Drugs Product Portfolio
  12. 6.2.5 Kono Recent Developments
  13. 6.3 DC chemicals
  14. 6.3.1 DC chemicals Company Information
  15. 6.3.2 DC chemicals Business Overview
  16. 6.3.3 DC chemicals Hormone Antineoplastic Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 DC chemicals Hormone Antineoplastic Drugs Product Portfolio
  18. 6.3.5 DC chemicals Recent Developments
  19. 6.4 Medbio
  20. 6.4.1 Medbio Company Information
  21. 6.4.2 Medbio Business Overview
  22. 6.4.3 Medbio Hormone Antineoplastic Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Medbio Hormone Antineoplastic Drugs Product Portfolio
  24. 6.4.5 Medbio Recent Developments
  25. 6.5 Acmec
  26. 6.5.1 Acmec Company Information
  27. 6.5.2 Acmec Business Overview
  28. 6.5.3 Acmec Hormone Antineoplastic Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Acmec Hormone Antineoplastic Drugs Product Portfolio
  30. 6.5.5 Acmec Recent Developments
  31. 6.6 Aladdin
  32. 6.6.1 Aladdin Company Information
  33. 6.6.2 Aladdin Business Overview
  34. 6.6.3 Aladdin Hormone Antineoplastic Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Aladdin Hormone Antineoplastic Drugs Product Portfolio
  36. 6.6.5 Aladdin Recent Developments
  37. 6.7 Revere
  38. 6.7.1 Revere Company Information
  39. 6.7.2 Revere Business Overview
  40. 6.7.3 Revere Hormone Antineoplastic Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Revere Hormone Antineoplastic Drugs Product Portfolio
  42. 6.7.5 Revere Recent Developments
  43. 6.8 Pfizer Inc.
  44. 6.8.1 Pfizer Inc. Company Information
  45. 6.8.2 Pfizer Inc. Business Overview
  46. 6.8.3 Pfizer Inc. Hormone Antineoplastic Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Inc. Hormone Antineoplastic Drugs Product Portfolio
  48. 6.8.5 Pfizer Inc. Recent Developments
  49. 6.9 Baxter International Inc.
  50. 6.9.1 Baxter International Inc. Company Information
  51. 6.9.2 Baxter International Inc. Business Overview
  52. 6.9.3 Baxter International Inc. Hormone Antineoplastic Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Baxter International Inc. Hormone Antineoplastic Drugs Product Portfolio
  54. 6.9.5 Baxter International Inc. Recent Developments
  55. 6.10 Hikma Pharmaceuticals Plc.
  56. 6.10.1 Hikma Pharmaceuticals Plc. Company Information
  57. 6.10.2 Hikma Pharmaceuticals Plc. Business Overview
  58. 6.10.3 Hikma Pharmaceuticals Plc. Hormone Antineoplastic Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Hikma Pharmaceuticals Plc. Hormone Antineoplastic Drugs Product Portfolio
  60. 6.10.5 Hikma Pharmaceuticals Plc. Recent Developments
7 North America by Country
  1. 7.1 North America Hormone Antineoplastic Drugs Sales by Country
  2. 7.1.1 North America Hormone Antineoplastic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Hormone Antineoplastic Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Hormone Antineoplastic Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Hormone Antineoplastic Drugs Market Size by Country
  6. 7.2.1 North America Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Hormone Antineoplastic Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Hormone Antineoplastic Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Hormone Antineoplastic Drugs Sales by Country
  2. 8.1.1 Europe Hormone Antineoplastic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Hormone Antineoplastic Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Hormone Antineoplastic Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Hormone Antineoplastic Drugs Market Size by Country
  6. 8.2.1 Europe Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Hormone Antineoplastic Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Hormone Antineoplastic Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Hormone Antineoplastic Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Hormone Antineoplastic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Hormone Antineoplastic Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Hormone Antineoplastic Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Hormone Antineoplastic Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Hormone Antineoplastic Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Hormone Antineoplastic Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Hormone Antineoplastic Drugs Sales by Country
  2. 10.1.1 South America Hormone Antineoplastic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Hormone Antineoplastic Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Hormone Antineoplastic Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Hormone Antineoplastic Drugs Market Size by Country
  6. 10.2.1 South America Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Hormone Antineoplastic Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Hormone Antineoplastic Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Hormone Antineoplastic Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Hormone Antineoplastic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Hormone Antineoplastic Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Hormone Antineoplastic Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Hormone Antineoplastic Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Hormone Antineoplastic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Hormone Antineoplastic Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Hormone Antineoplastic Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Hormone Antineoplastic Drugs Value Chain Analysis
  2. 12.1.1 Hormone Antineoplastic Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Hormone Antineoplastic Drugs Production Mode & Process
  7. 12.2 Hormone Antineoplastic Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Hormone Antineoplastic Drugs Distributors
  10. 12.2.3 Hormone Antineoplastic Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst